sandos-logo.jpg
Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics
October 11, 2021 03:15 ET | Novartis Pharma AG
Sandoz gains rights to three established brands sold in more than 100 marketsTransaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading...
Sandoz logo
Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs
October 01, 2021 11:52 ET | Novartis Pharma AG
Company previously disclosed settlement agreement in principle and fully provisioned for this resolution Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz, has...
NOVARTIS logo.jpg
Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions
September 30, 2021 01:15 ET | Novartis Pharma AG
Reached nearly 29 million patients to date in 2021 through our flagship programs and strategic innovative brandsAnnounced a planned 10-year commitment with historically black colleges and universities...
NOVARTIS logo.jpg
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
September 19, 2021 07:30 ET | Novartis Pharma AG
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced...
NOVARTIS logo.jpg
Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
September 17, 2021 07:30 ET | Novartis Pharma AG
PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissuesAt 24 weeks,...
NOVARTIS logo.jpg
Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021
September 16, 2021 18:05 ET | Novartis Pharma AG
New quality of life data for 177Lu-PSMA-617 plus standard of care shows delay in worsening of health-related quality of life (HRQoL) and pain in heavily pre-treated patients with PSMA-positive...
Sandoz logo
Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine
September 08, 2021 07:30 ET | Novartis Pharma AG
Sandoz enters into commercialization agreement for biosimilar bevacizumab with Bio-Thera Solutions, Ltd., for treatment of multiple types of cancers1,2Sandoz is committed to building on its leading...
NOVARTIS logo.jpg
World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran)
August 31, 2021 19:01 ET | Novartis Pharma AG
Agreement follows positive NICE recommendation and commits to deliver Leqvio® (inclisiran) access via a population health management approach identifying eligible patients across England1 Over three...
NOVARTIS logo.jpg
Novartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other key data at ESMO
August 30, 2021 01:15 ET | Novartis Pharma AG
New Kisqali® (ribociclib)* overall survival (OS) results from MONALEESA-2 trial in HR+/HER2− advanced breast cancer patients in the first-line settingHealth-related quality of life, pain and safety...
NOVARTIS logo.jpg
Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma
August 24, 2021 01:15 ET | Novartis Pharma AG
Phase III BELINDA study did not meet primary endpoint of event-free survival for patients with aggressive B-cell non-Hodgkin lymphoma who had primary refractory disease or who relapsed within 12...